Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

The present invention relates to a method of cultivating an epithelial stem/progenitor cell population of the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types.

The present invention relates to a reliable method for producing amniotic-like epithelial cells, using a new methodology. The invention also relates to a composition and the use of said composition comprising amniotic-like epithelial cells or a preparation derived therefrom. Said cells may have particular utility in regenerative medicine, research and/or cosmetic preparations.

Disclosed herein include methods and compositions for culture medias for in vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.

Xenograft egg models comprising a fertilized non-mammalian egg comprising an ablated immune system, a first plurality of mammalian cells and a second plurality of mammalian cells, wherein the second plurality comprises immune cells are provided. Methods of producing the xenograft egg model as well as using the xenograft egg model for screening are also provided.

The disclosure relates to the establishment of a cell line having immune tolerance property using an optimal temperature profiling technique under a human body-like environment, and use thereof. The stem cell line exhibits immune tolerance property as they consecutively secret and express HLA-G proteins, and the culture medium of the stem cells contains a large amount of proteins capable of recovering various physiological functions and extracellular vesicles, and thus, the novel cell line or a culture medium thereof can be effectively used in various industries such as medicines and cosmetics.

The present disclosure relates to methods for producing lentiviral vectors using mammalian cells. Specifically, the methods utilize three plasmids, rather than four, to provide the required packaging elements and transfer vector to a cell, allowing for the production of a large number of lentiviral vectors in mammalian cells, including suspension-based cells. These methods allow for the production of lentiviral vectors that can be tailored to include a specific gene of interest.

The present invention discloses a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman. Based on a specific antigen or combination expressed on the surface or inside of specific trophoblast cells, the designed microfluidic sorting chip or flow cytometer is used in the method to perform cell sorting of a cell suspension of a placental trophoblast sample, thus obtaining isolated and purified placental trophoblast cells. Compared with conventional methods, the method of the present invention has the advantages of non-invasively obtaining specimens and good specificity. Moreover, the method causes low risk of infection and abortion, allows earlier sampling time and can achieve the synchronous labeling of a plurality of antigens as well as identification and sorting of characteristic fluorescence signals; and the method has greatly improved accuracy and higher reliability and broader coverage area of detection results.

Uncultured amniotic cell and protein fraction products derived from amniotic fluid and methods of preparing and using those compositions are provided. According to the methods of the present invention, uncultured amniotic cell and protein products may be derived from a large sample of amniotic fluid to provide a higher concentration of tissue regeneration components. Described are methods for separating uncultured amniotic cells or protein fractions from other components of amniotic fluid and the resulting uncultured amniotic cell and protein products. Furthermore, the present invention includes methods for delivering the uncultured amniotic cell and protein products to the skin and eye, including before, during, or after a treatment procedure.